{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:34:49Z","timestamp":1760189689854,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"EMD Serono Inc, Rockland, MA, a business of Merck KGaA, Darmstadt, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12325-019-01034-0","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T10:02:56Z","timestamp":1564135376000},"page":"2327-2341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8209-8843","authenticated-orcid":false,"given":"Tereza","family":"Lanitis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Proskorovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apoorva","family":"Ambavane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murtuza","family":"Bharmal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemant","family":"Phatak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,26]]},"reference":[{"issue":"4","key":"1034_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/0272989X17697019","volume":"37","author":"N Hawkins","year":"2017","unstructured":"Hawkins N, Grieve R. Extrapolation of survival data in cost-effectiveness analyses: the need for causal clarity. Med Decis Making. 2017;37(4):337\u20139.","journal-title":"Med Decis Making"},{"issue":"5","key":"1034_CR2","first-page":"448","volume":"22","author":"A Pannier","year":"2016","unstructured":"Pannier A, Dunn JD. AMCP Format for Formulary Submissions, Version 40. J Manag Care Spec Pharm. 2016;22(5):448.","journal-title":"J Manag Care Spec Pharm"},{"key":"1034_CR3","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. \n                    https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/introduction\n                    \n                  . Accessed 29 October 2018."},{"issue":"6","key":"1034_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","volume":"33","author":"N Latimer","year":"2013","unstructured":"Latimer N. Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743\u201354.","journal-title":"Med Decis Making"},{"issue":"8","key":"1034_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40273-013-0064-3","volume":"31","author":"KJ Ishak","year":"2013","unstructured":"Ishak KJ, Kreif N, Benedict A, Muszbek N. Overview of parametric survival analysis for health-economic applications. Pharmacoeconomics. 2013;31(8):663\u201375.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1034_CR6","doi-asserted-by":"publisher","first-page":"194494","DOI":"10.1371\/journal.pone.0194494","volume":"13","author":"K Logviss","year":"2018","unstructured":"Logviss K, Krievins D, Purvina S. Characteristics of clinical trials in rare vs common diseases: a register-based Latvian study. PLoS One. 2018;13(4):194494.","journal-title":"PLoS One"},{"key":"1034_CR7","unstructured":"National Institute for Health and Care Excellence (NICE). Nivolumab for treating advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance TA384. 2016. \n                    https:\/\/www.nice.org.uk\/guidance\/ta384\n                    \n                  . Accessed 8 Aug 2018."},{"key":"1034_CR8","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for advanced melanoma not previously treated with ipilimumab. NICE technology appraisal guidance TA366. 2015. \n                    https:\/\/www.nice.org.uk\/guidance\/ta366\n                    \n                  . Accessed 8 Aug 2018."},{"key":"1034_CR9","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab. NICE technology appraisal guidance TA357. 2015. \n                    https:\/\/www.nice.org.uk\/guidance\/ta357\n                    \n                  . Accessed 8 Aug 2018."},{"issue":"1","key":"1034_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/blr.2015.9999","volume":"34","author":"E Kepplinger","year":"2015","unstructured":"Kepplinger E. FDA\u2019s expedited approval mechanisms for new drug products. Biotechnol Law Rep. 2015;34(1):15\u201337.","journal-title":"Biotechnol Law Rep"},{"key":"1034_CR11","unstructured":"U.S. Food and Drug Administration, Center for drug evaluation and Research. Advancing health through innovation\u20142017 new drug therapy approvals. January 2017. \n                    https:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ReportsBudgets\/UCM591976.pdf\n                    \n                  . Accessed 8 Aug 2018."},{"key":"1034_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3332\/ecancer.2015.604","volume":"9","author":"F Ades","year":"2015","unstructured":"Ades F, Yamaguchi N. WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results? Ecancermedicalscience. 2015;9:604.","journal-title":"Ecancermedicalscience"},{"issue":"23","key":"1034_CR13","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412\u201320.","journal-title":"Clin Cancer Res"},{"key":"1034_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2051-1426-1-18","volume":"1","author":"TT Chen","year":"2013","unstructured":"Chen TT. Statistical issues and challenges in immuno-oncology. J Immunother Cancer. 2013;1:18.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1034_CR15","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s40273-017-0558-5","volume":"35","author":"E Gibson","year":"2017","unstructured":"Gibson E, Koblbauer I, Begum N, et al. Modelling the survival outcomes of immuno-oncology drugs in economic evaluations: a systematic approach to data analysis and extrapolation. Pharmacoeconomics. 2017;35(12):1257\u201370.","journal-title":"Pharmacoeconomics"},{"key":"1034_CR16","unstructured":"Briggs A, Haddad R, Muszbek, Zhang Y. Developing cost-effectiveness models to assess value of immuno-oncology therapies: challenges and approaches. International Society for Pharmacoeconomics and Outcomes Research, 22nd Annual International Meeting. May 20\u201324, 2017; Boston, MA: Workshop 3."},{"key":"1034_CR17","unstructured":"Zhang Y, Mukhopadhyay P, Briggs A, Latimer N, Huang Min. Determining the value of long term outcomes associated with immuno-oncology therapies\u2014challenges and approaches for OS extrapolations. International Society for Pharmacoeconomics and Outcomes Research 20th Annual European Congress. November 4\u20138, 2017; Glasgow, Scotland: Workshop 11."},{"issue":"9","key":"1034_CR18","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40273-019-00806-4","volume":"37","author":"Mario J. N. M. Ouwens","year":"2019","unstructured":"Ouwens M, Mukhopadhyay P, Zhang Y, Huang M, Latimer N, Briggs A. Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations. PharmacoEconomics. 2019. \n                    https:\/\/doi.org\/10.1007\/s40273-019-00806-4\n                    \n                  .","journal-title":"PharmacoEconomics"},{"key":"1034_CR19","unstructured":"Ishak KJ, Muszbek N, Proskorovsky I, Zhang Y. Projecting survival with immuno-oncology therapies: new challenges and new approaches. International Society for Pharmacoeconomics and Outcomes Research, 19th Annual European Congress. 29 October\u20132 November 2016, Austria, Vienna."},{"key":"1034_CR20","unstructured":"Ishak KJ, Proskorovsky I, Muszbek N. Projecting overall survival with immuno-oncology treatments. The Evidence Forum. 2016. \n                    https:\/\/www.evidera.com\/wp-content\/uploads\/2016\/10\/Projecting-Overall-Survival-with-Immuno-Oncology-Treatments.pdf\n                    \n                  . Accessed 25 June 2019."},{"key":"1034_CR21","unstructured":"U.S. Food and Drug Administration. Avelumab (Bavencio). \n                    https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm547965.htm\n                    \n                  . Accessed 29 Oct 2018."},{"issue":"1","key":"1034_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40425-017-0310-x","volume":"6","author":"HL Kaufman","year":"2018","unstructured":"Kaufman HL, Russell JS, Hamid O, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after \u2265\u20091\u00a0year of follow-up JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018;6(1):7.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"1034_CR23","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385.","journal-title":"Lancet Oncol"},{"issue":"19","key":"1034_CR24","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.2217\/fon-2017-0187","volume":"13","author":"CL Cowey","year":"2017","unstructured":"Cowey CL, Mahnke L, Espirito J, Helwig C, Oksen D, Bharmal M. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol. 2017;13(19):1699\u2013710.","journal-title":"Future Oncol"},{"issue":"4","key":"1034_CR25","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jval.2016.04.011","volume":"20","author":"M Othus","year":"2017","unstructured":"Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. Accounting for cured patients in cost-effectiveness analysis. Value Health. 2017;20(4):705\u20139.","journal-title":"Value Health"},{"issue":"Suppl 1","key":"1034_CR26","first-page":"PCP24","volume":"21","author":"J Ishak","year":"2018","unstructured":"Ishak J, Villalobos CF, Proskorovsky I. Projecting survival with cure mixture models: when are the data mature enough for reliable analysis? Value Health. 2018;21(Suppl 1):PCP24.","journal-title":"Value Health"},{"key":"1034_CR27","unstructured":"Latimer NR. National Institute for Health and Care Excellence (NICE); Mar 2013. NICE DSU Technical Support Document No. 14. NICE Decision Support Unit Technical Support Documents. Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data. \n                    http:\/\/nicedsu.org.uk\/technical-support-documents\/technical-support-documents\n                    \n                  . Accessed 8 Aug 2018."},{"issue":"4","key":"1034_CR28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00262-018-02295-4","volume":"68","author":"SP D\u2019Angelo","year":"2019","unstructured":"D\u2019Angelo SP, Hunger M, Brohl AS, et al. Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. Cancer Immunol Immunother. 2019;68(4):609\u201318.","journal-title":"Cancer Immunol Immunother"},{"issue":"5_suppl","key":"1034_CR29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1200\/JCO.2018.36.5_suppl.192","volume":"36","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Russell JS, Bhatia S, et al. 18-month efficacy and safety update from JAVELIN Merkel 200 part A. a phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy. J Clin Oncol. 2018;36(5_suppl):192.","journal-title":"J Clin Oncol."},{"key":"1034_CR30","unstructured":"The Human Mortality Database. United States Mortality Database (2014). \n                    http:\/\/www.mortality.org\/\n                    \n                  . Accessed 10 Oct 2017."},{"issue":"1","key":"1034_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12955-017-0815-5","volume":"15","author":"M Bharmal","year":"2017","unstructured":"Bharmal M, Fofana F, Barbosa CD, et al. Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma. Health Qual Life Outcomes. 2017;15(1):247.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"1034_CR32","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","volume":"15","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health. 2012;15(6):843\u201350.","journal-title":"Value Health"},{"issue":"5_suppl","key":"1034_CR33","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.1200\/JCO.2018.36.15_suppl.9507","volume":"36","author":"P Nghiem","year":"2018","unstructured":"Nghiem P, Bhatia S, Brohl AS, et al. Two-year efficacy and safety update from JAVELIN Merkel 200 part A: a registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy. J Clin Oncol. 2018;36(5_suppl):9507.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1034_CR34","doi-asserted-by":"publisher","first-page":"e0203406","DOI":"10.1371\/journal.pone.0203406","volume":"13","author":"B Deniz","year":"2018","unstructured":"Deniz B, Altincatal A, Ambavane A, et al. Application of dynamic modeling for survival estimation in advanced renal cell carcinoma. PLoS One. 2018;13(8):e0203406.","journal-title":"PLoS One"},{"issue":"4","key":"1034_CR35","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582\u20138.","journal-title":"Ann Oncol"},{"key":"1034_CR36","doi-asserted-by":"crossref","unstructured":"Bullement A, Amin A, Stapelkamp C, et al. Modelling overall survival in immunotherapy using parametric techniques: avelumab in previously treated metastatic Merkel cell carcinoma. International Society for Pharmacoeconomics and Outcomes Research 21st Annual European Congress. November 1014, 2018, Barcelona, Spain.","DOI":"10.1016\/j.jval.2018.09.062"},{"key":"1034_CR37","unstructured":"National Institute for Health and Care Excellence (NICE). Avelumab for treating metastatic merkel cell carcinoma. NICE technology appraisal guidance TA517. 2018. \n                    https:\/\/www.nice.org.uk\/guidance\/ta517\/\n                    \n                  . Accessed 8 Aug 2018."},{"issue":"Suppl 1","key":"1034_CR38","doi-asserted-by":"publisher","first-page":"S224","DOI":"10.1016\/j.jval.2018.04.1516","volume":"21","author":"D Alexiou","year":"2018","unstructured":"Alexiou D, Chatzitheofilou I, Pi Blanque A. A review of NICE technology appraisals in oncology using single arm trials evidence. Value Health. 2018;21(Suppl 1):S224. \n                    https:\/\/doi.org\/10.1016\/j.jval.2018.04.1516\n                    \n                  .","journal-title":"Value Health"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01034-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01034-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01034-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T23:04:27Z","timestamp":1595631867000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01034-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,26]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1034"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01034-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2019,7,26]]},"assertion":[{"value":"20 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}